Eris LifesciencesBOM:540596 +0.14%91 Gross Margin % is 75.38% as of Mar. 2026, which is 6% below its 10-year median of 80.43. GuruFocus rates BOM:540596 with a GF Score™ of 91/100 and a GF Value™ of ₹1,646.98 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 937 Drug Manufacturers companies, Eris Lifesciences ranks better than 87.51% on this metric.
Eris Lifesciences Ltd gross margin has been in long-term decline. The average rate of decline per year is -1.5%.
The historical rank and industry rank for Eris Lifesciences's Gross Margin % or its related term are showing as below:
BOM:540596'
s Gross Margin % Range Over the Past 10 Years
Min: 74.46 Med: 80.43 Max: 85.71
Current: 74.46
During the past 13 years, the highestGross Margin % of Eris Lifesciences was 85.71%. The lowest was 74.46%. And the median was 80.43%.
BOM:540596's Gross Margin % is ranked better than 87.51% of 937
companies
in the Drug Manufacturers industry
Industry Median: 48.46
vs BOM:540596: 74.46
Eris Lifesciences had a gross margin of 75.38% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Eris Lifesciences was -1.50% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Eris Lifesciences had a gross margin of 75.38% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Eris Lifesciences Gross Margin % Related Terms
Eris Lifesciences Gross Margin % Historical Data
* Premium members only.
The historical data trend for Eris Lifesciences's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:540596 vs ZTS, UTHR: Gross Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Eris Lifesciences's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eris Lifesciences Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Eris Lifesciences's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Eris Lifesciences's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Eris Lifesciences (BOM:540596) has a Gross Margin % of 75.38% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Eris Lifesciences and its competitors. This is near median its historical median of 80.43. Over the past decade, Eris Lifesciences' Gross Margin % has ranged from 74.46 to 85.71. According to the industry distribution chart, Eris Lifesciences ranks #117 out of 937 companies in the Drug Manufacturers industry, placing it in the top 12.5%.
Is Eris Lifesciences' Gross Margin % too high?
Eris Lifesciences' current Gross Margin % of 75.38% is near median its 10-year median of 80.43. Over the past 10 years, this metric has ranged from a low of 74.46 to a high of 85.71. The Drug Manufacturers industry median Gross Margin % is 48.46. Eris Lifesciences' value of 75.38% is 55.6% above this industry median. Based on the distribution chart, Eris Lifesciences ranks #117 out of 937 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Eris Lifesciences has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eris Lifesciences' Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Eris Lifesciences ranks #117 out of 937 companies for Gross Margin %. This places Eris Lifesciences in the top 13% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 48.46. Eris Lifesciences' value of 75.38% is 55.6% above this benchmark. Historically, Eris Lifesciences' own Gross Margin % has ranged from 74.46 to 85.71 over the past decade. While the company's 10-year median is 80.43 vs. the industry median of 48.46, Eris Lifesciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.46, based on 937 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eris Lifesciences's current Gross Margin % of 75.38% is 55.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Eris Lifesciences and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eris Lifesciences's current Gross Margin % is 75.38%, which is near median its own 10-year median of 80.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eris Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Eris Lifesciences (BOM:540596) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹1,646.98, compared to a current price of ₹1,447.25 — trading 12.1% below its estimated fair value. The current Gross Margin % is 75.38%, which is near median its 10-year median of 80.43 and 55.6% above the Drug Manufacturers industry median of 48.46. Eris Lifesciences' overall GF Score™ is 91/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Eris Lifesciences (BOM:540596), the current Gross Margin % is 75.38% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eris Lifesciences (BOM:540596) Overvalued in 2026?
Based on GuruFocus' analysis, Eris Lifesciences stock appears to be undervalued.
The current stock price of ₹1,447.25 is trading 12.1% below its estimated GF Value™ of ₹1,646.98.
GuruFocus considers Eris Lifesciences to be Modestly Undervalued.
Key valuation signals for BOM:540596:
Gross Margin %: 75.38% (near median its 10-year median of 80.43)
GF Value™: ₹1,646.98 vs. price of ₹1,447.25 (12.1% below fair value)
Industry Position: 55.6% above the Drug Manufacturers median (#117 of 937)
No single metric tells the full story. See the BOM:540596 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eris Lifesciences Ltd is an India-based company engaged in the manufacturing and sale of branded pharmaceutical formulations. It focuses on Lifestyle therapies such as Diabetes Care, Cardiac Care, Nutrition, Central Nervous System, and others. The company operates in a single segment that is pharmaceuticals. Some of its brands include Glimisave, Cyblex, Eritel, Atorsave and Crevast. The company works basically within India and International with the majority of revenue from India.
91GF Score
Get the complete analysis for BOM:540596
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:540596 has been successfully added to your 
